These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 23264342

  • 1. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.
    Ciccia F, Giardina A, Rizzo A, Guggino G, Cipriani P, Carubbi F, Giacomelli R, Triolo G.
    Ann Rheum Dis; 2013 May; 72(5):782-3. PubMed ID: 23264342
    [No Abstract] [Full Text] [Related]

  • 2. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.
    Ciccia F, Guggino G, Rizzo A, Alessandro R, Carubbi F, Giardina A, Cipriani P, Ferrante A, Cannizzaro A, Giacomelli R, Triolo G.
    Rheumatology (Oxford); 2014 Jul; 53(7):1313-20. PubMed ID: 24602921
    [Abstract] [Full Text] [Related]

  • 3. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
    Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, Visser A, Vissink A, Kallenberg CG, Kroese FG, Bos NA.
    Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
    [Abstract] [Full Text] [Related]

  • 4. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
    Cornec D, Costa S, Devauchelle-Pensec V, Jousse-Joulin S, Marcorelles P, Berthelot JM, Chiche L, Hachulla E, Hatron PY, Goeb V, Vittecoq O, Saraux A, Pers JO.
    J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
    [Abstract] [Full Text] [Related]

  • 5. NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment.
    Pontarini E, Sciacca E, Grigoriadou S, Rivellese F, Lucchesi D, Fossati-Jimack L, Coleby R, Chowdhury F, Calcaterra F, Tappuni A, Lewis MJ, Fabris M, Quartuccio L, Bella SD, Bowman S, Pitzalis C, Mavilio D, De Vita S, Bombardieri M.
    Front Immunol; 2021 Feb; 12():706737. PubMed ID: 34594326
    [Abstract] [Full Text] [Related]

  • 6. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
    Nikiphorou E, Hall FC.
    Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401
    [No Abstract] [Full Text] [Related]

  • 7. Does rituximab help patients with primary Sjögren syndrome?
    Ann Intern Med; 2014 Feb 18; 160(4):I-11. PubMed ID: 24727838
    [No Abstract] [Full Text] [Related]

  • 8. Summaries for patients. Does rituximab help patients with primary Sjögren syndrome?
    Ann Intern Med; 2014 Feb 18; 160(4):I-11. PubMed ID: 25006621
    [No Abstract] [Full Text] [Related]

  • 9. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.
    Moerman RV, Arends S, Meiners PM, Brouwer E, Spijkervet FK, Kroese FG, Vissink A, Bootsma H.
    Ann Rheum Dis; 2014 Feb 18; 73(2):472-4. PubMed ID: 23940214
    [No Abstract] [Full Text] [Related]

  • 10. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab.
    Uraoka Y, Tanigawa T, Watanabe K, Machida H, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Watanabe T, Fujiwara Y, Arakawa T.
    Am J Gastroenterol; 2012 Aug 18; 107(8):1266-8. PubMed ID: 22859008
    [No Abstract] [Full Text] [Related]

  • 11. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H.
    Ann Rheum Dis; 2012 Aug 18; 71(8):1297-302. PubMed ID: 22258489
    [Abstract] [Full Text] [Related]

  • 12. Anion exchanger immunoreactivity in human salivary glands in health and Sjögren's syndrome.
    Vázquez JJ, Vázquez M, Idoate MA, Montuenga L, Martínez-Ansó E, Castillo JE, García N, Medina JF, Prieto J.
    Am J Pathol; 1995 Jun 18; 146(6):1422-32. PubMed ID: 7778681
    [Abstract] [Full Text] [Related]

  • 13. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.
    Alunno A, Carubbi F, Bistoni O, Caterbi S, Bartoloni E, Di Benedetto P, Cipriani P, Giacomelli R, Gerli R.
    Clin Exp Immunol; 2016 Jun 18; 184(3):284-92. PubMed ID: 26814615
    [Abstract] [Full Text] [Related]

  • 14. A role for lymphotoxin in primary Sjogren's disease.
    Shen L, Suresh L, Wu J, Xuan J, Li H, Zhang C, Pankewycz O, Ambrus JL.
    J Immunol; 2010 Nov 15; 185(10):6355-63. PubMed ID: 20952683
    [Abstract] [Full Text] [Related]

  • 15. Acquired factor VIII inhibitor in Sjögren's syndrome.
    Vintimilla M, Joseph A, Ranganathan P.
    Arthritis Care Res (Hoboken); 2010 Jul 15; 62(7):1047-50. PubMed ID: 20589701
    [No Abstract] [Full Text] [Related]

  • 16. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.
    Pollard RP, Abdulahad WH, Bootsma H, Meiners PM, Spijkervet FK, Huitema MG, Burgerhof JG, Vissink A, Kroese FG.
    Ann Rheum Dis; 2013 Dec 15; 72(12):2048-50. PubMed ID: 23864239
    [No Abstract] [Full Text] [Related]

  • 17. Expression of the interferon-gamma-inducible 10-kd protein and CXC receptor 3 in the salivary gland lesions of patients with Sjögren's syndrome: comment on the article by Ogawa et al.
    Sfriso P, Calabrese F, Grava C, Agostini C, Punzi L, Oliviero F, Botsios C, Ostuni PA, Todesco S.
    Arthritis Rheum; 2003 Aug 15; 48(8):2390-1; author reply 2391-2. PubMed ID: 12905497
    [No Abstract] [Full Text] [Related]

  • 18. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
    Atzeni F, Sarzi-Puttini P.
    Reumatismo; 2010 Aug 15; 62(2):87-8. PubMed ID: 20657883
    [No Abstract] [Full Text] [Related]

  • 19. Sjögren's syndrome: a quintessential B cell-induced autoimmune disease.
    Youinou P.
    Joint Bone Spine; 2008 Jan 15; 75(1):1-2. PubMed ID: 17905630
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
    Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, Pantano I, Liakouli V, Alvaro S, Alunno A, Manzo A, Ciccia F, Gerli R, Triolo G, Giacomelli R.
    Arthritis Res Ther; 2013 Oct 30; 15(5):R172. PubMed ID: 24286296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.